P/B
5,8
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
$751.6M
Market Cap • 9/10/2026
1997
(29 years)
Founded
2023
(3 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
6,3
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,3
EPS
—
Market Cap
Market Cap
751,6M
EV
737,2M
EV/Revenue
6,2
EV/EBITDA
-55,8
EV/EBIT
-44,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-3,1%
Total Yield
-3,1%
Payout
0%
Retained Earnings
-134,3M
Profitability
Gross Margin
94,3%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
27,7%
Capex/Revenue
1%
Capex/D&A
36,2%
Capex/OCF
-10%
SBC/OCF
—
% PPE
13,7%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
85,1%
CAGR Op. Income 5Y
-26,4%
CAGR Net Income 5Y
-24%
CAGR EPS 5Y
-65,9%
CAGR OCF 5Y
-30,9%
Leverage
N.D./EBITDA
5,4
Debt/Equity
0%
Current Ratio
4,3
Quick Ratio
3,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!